Section 3: Production and Compounding

3PC-069

IMPROVING SAFETY AND QUALITY FOR ASEPTIC TRANSFER PROCEDURES IN HOSPITAL PHARMACIES

3PC-068

LONG TERM STABILITY OF CO-ADMINISTRATION OF BUMETANIDE AND SCOPOLAMINE FOR THE PALLIATIVE CARE UNIT

3PC-067

KEY ROLE OF HOSPITAL PHARMACY IN A NON-PROFIT STUDY INVOLVING RUXOLITINIB 5mg CPS: IMPLEMENTATION AND QUALITY ASSURANCE OF AN INVESTIGATIONAL MANUFACTURING PRODUCT

3PC-066

COMPOUNDING AN EYE DROP FORMULATION OF TOPICAL INSULIN FOR CORNEAL DEFECTS REFRACTORY TO PREVIOUS TREATMENT: EXPERIENCE IN REAL CLINICAL PRACTICE

3PC-065

IMPACT OF LIGHT STRESS ON THE ISOFORM PROFILE OF NIVOLUMAB (OPDIVO) IN OPENED VIALS ESTIMATED BY (RP)UHPLC-UV-(HESI/ORBITRAP)-MS

3PC-064

A MULTICENTRE STUDY COMPARING CHEMOTHERAPY PREPARATIONS USING A DIGITAL VIDEO MONITORING

3PC-063

PERFORMANCE QUALIFICATION OF ROBOTIC SYSTEM FOR CYTOTOXIC DRUG PREPARATION IN A FULLY GMP COMPLIANT HOSPITAL PHARMACY

3PC-062

IMPACT OF THE PREPARATION OF THE 1.0 MG/ML NIVOLUMAB CLINICAL SOLUTION ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: NaCl AND GLUCOSE CONCENTRATION AND AGITATION EFFECT

3PC-061

PHYSICOCHEMICAL STABILITY OF CLOXACILLIN SOLUTION IN POLYPROPYLENE SYRINGES AT 125 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER

3PC-060

PHYSICOCHEMICAL STABILITY OF VANCOMYCIN SOLUTION IN ELASTOMERIC DEVICES AT 37.5 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER

3PC-059

PHYSICOCHEMICAL STABILITY OF CEFTOLOZANE/TAZOBACTAM IN POLYPROPYLENE SYRINGES AT 61.5/31.25 mg/mL AND IN ELASTOMERIC DEVICES AT 25.0/12.5 mg/mL

3PC-058

PHYSICOCHEMICAL STABILITY OF MEROPENEM IN POLYPROPYLENE SYRINGES AT 41.7 mg/mL FOR INTENSIVE CARE UNITS

3PC-055

STABILITY OF UROKINASE IN CITRATE BASED SOLUTIONS

3PC-056

A STABLE READY-TO-USE FORMULATION OF PHENYLEPHRINE HCL IN SYRINGES

3PC-057

USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY

Pages